Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Equity Average (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Equity Average for 8 consecutive years, with $509.8 million as the latest value for Q1 2026.

  • Quarterly Equity Average rose 1.16% to $509.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $509.8 million through Feb 2026, up 1.16% year-over-year, with the annual reading at $532.9 million for FY2025, 46.5% up from the prior year.
  • Equity Average for Q1 2026 was $509.8 million at Nurix Therapeutics, up from $455.5 million in the prior quarter.
  • The five-year high for Equity Average was $509.8 million in Q1 2026, with the low at $184.6 million in Q1 2024.
  • Average Equity Average over 5 years is $346.0 million, with a median of $323.1 million recorded in 2022.
  • The sharpest move saw Equity Average tumbled 36.09% in 2024, then soared 172.97% in 2025.
  • Over 5 years, Equity Average stood at $323.1 million in 2022, then crashed by 32.79% to $217.2 million in 2023, then soared by 108.11% to $451.9 million in 2024, then rose by 0.79% to $455.5 million in 2025, then rose by 11.93% to $509.8 million in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $509.8 million, $455.5 million, and $409.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.